NewAmsterdam Pharma Phase 3 Drug Combo Study Hits Main Endpoints

By MarketWatch | Nov 20, 2024 at 07:35 AM EST

NewAmsterdam Pharma's cholesterol drug combination met key goals in a late-stage study, leading to plans for regulatory approval. The Phase 3 trial showed significant reduction in LDL cholesterol in adults with certain conditions. Regulatory filings will be pursued globally. Trading of NewAmsterdam shares was halted.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.